Cancer immunotherapy comes of age
| Autor: | Ira Mellman, Glenn Dranoff, George Coukos |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Oncology medicine.medical_specialty T-Lymphocytes medicine.medical_treatment Antineoplastic Agents Context (language use) Ipilimumab Active immunotherapy Cancer Vaccines Article Immune system Cancer immunotherapy Neoplasms Internal medicine medicine Humans Immunologic Factors Multidisciplinary business.industry Antibodies Monoclonal Prostatic Neoplasms Cancer Immunosuppression Immunotherapy medicine.disease Immunology business medicine.drug |
| Zdroj: | Nature. 480:480-489 |
| ISSN: | 1476-4687 0028-0836 |
| Popis: | Activating the immune system for therapeutic benefit in cancer has long been a dream of some immunologists, and even a few oncologists. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable has been the ability of the anti-CTLA4 antibody ipilimumab to achieve significant increases in survival of patients with metastatic melanoma, an indication where conventional therapies have failed. Viewed in the context of advances in understanding of how tolerance, immunity, and immunosuppression regulate anti-tumor immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path forward to obtaining durable, long-lasting responses in cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|